PLAT and ischemic stroke: Ischemic stroke is a devastating condition; the only current U.S. Food and Drug Administration-approved ischemic stroke therapy is thrombolysis by treatment with tissue plasminogen activator (tPA), but tPA also increases the risk of hemorrhage, which is associated with BBB disruption [72, 73].